NasdaqCM:PTE

Stock Analysis Report

Executive Summary

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States.

Snowflake

Fundamentals

Fair value with mediocre balance sheet.

Risks

  • PolarityTE has significant price volatility in the past 3 months.

Share Price & News

How has PolarityTE's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.3%

NasdaqCM:PTE

-0.8%

US Biotechs

-0.4%

US Market


1 Year Return

-76.1%

NasdaqCM:PTE

-3.7%

US Biotechs

4.3%

US Market

PTE underperformed the Biotechs industry which returned -4.9% over the past year.

PTE underperformed the Market in United States of America which returned 4.9% over the past year.


Share holder returns

PTEIndustryMarket
7 Day-6.3%-0.8%-0.4%
30 Day-16.9%2.0%2.8%
90 Day-46.3%-1.7%2.7%
1 Year-76.1%-76.1%-2.9%-3.7%6.6%4.3%
3 Year31.2%31.2%22.3%18.0%50.9%40.9%
5 Year-49.2%-64.1%10.4%5.6%55.3%38.2%

Price Volatility Vs. Market

How volatile is PolarityTE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PolarityTE undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

PolarityTE's share price is below the future cash flow value, and at a moderate discount (> 20%).

PolarityTE's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

PolarityTE is loss making, we can't compare its value to the US Biotechs industry average.

PolarityTE is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for PolarityTE, we can't assess if its growth is good value.


Price Based on Value of Assets

PolarityTE is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is PolarityTE expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

19.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

PolarityTE's revenue is expected to grow significantly at over 20% yearly.

PolarityTE is not considered high growth as it is expected to be loss making for the next 1-3 years.

PolarityTE's revenue growth is expected to exceed the United States of America market average.

Unable to compare PolarityTE's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare PolarityTE's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if PolarityTE will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has PolarityTE performed over the past 5 years?

-47.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

PolarityTE does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare PolarityTE's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare PolarityTE's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if PolarityTE has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if PolarityTE has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if PolarityTE improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is PolarityTE's financial position?


Financial Position Analysis

PolarityTE is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

PolarityTE's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

PolarityTE's level of debt (5.1%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 5.1% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 16.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

PolarityTE has less than a year of cash runway based on current free cash flow.

PolarityTE has less than a year of cash runway if free cash flow continues to grow at historical rates of 99.9% each year.


Next Steps

Dividend

What is PolarityTE's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate PolarityTE's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate PolarityTE's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as PolarityTE has not reported any payouts.

Unable to verify if PolarityTE's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as PolarityTE has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of PolarityTE's salary, the management and board of directors tenure and is there insider trading?

0.9yrs

Average management tenure


CEO

Denver Lough (37yo)

2.5yrs

Tenure

Dr. Denver M. Lough, M.D., Ph.D., has been the Chairman, Chief Executive Officer, Chief R&D Officer (on indefinite administrative leave) and President of PolarityTE, Inc. since December 1, 2016 and served  ...


Management Age and Tenure

0.9yrs

Average Tenure

48yo

Average Age

The average tenure for the PolarityTE management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.4yrs

Average Tenure

56yo

Average Age

The average tenure for the PolarityTE board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by PolarityTE individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$11,31513 Jun 19
Edward Swanson
EntityIndividual
Shares2,000
Max PriceUS$5.66
SellUS$318,97812 Jun 19
Steven Gorlin
EntityIndividual
Role
Member of the Board of Directors
Shares53,700
Max PriceUS$5.94
BuyUS$11,36706 Jun 19
Edward Swanson
EntityIndividual
Shares2,000
Max PriceUS$5.68
BuyUS$207,55006 Jun 19
David Seaburg
EntityIndividual
Role
President of Corporate Development & Director
Member of the Board of Directors
Shares35,000
Max PriceUS$5.93
BuyUS$186,51906 Jun 19
Paul Mann
EntityIndividual
Role
Chief Financial Officer
Shares35,000
Max PriceUS$5.33
BuyUS$84,47106 Jun 19
Peter Cohen
EntityIndividual
Shares15,000
Max PriceUS$5.63
SellUS$5,569,09709 Oct 18
John Stetson
EntityIndividual
Shares297,500
Max PriceUS$19.27
BuyUS$8,63319 Sep 18
Edward Swanson
EntityIndividual
Shares500
Max PriceUS$17.27
BuyUS$344,71619 Sep 18
Paul Mann
EntityIndividual
Role
Chief Financial Officer
Shares20,000
Max PriceUS$17.24
BuyUS$116,36618 Sep 18
Ramses Erdtmann
EntityIndividual
Shares6,680
Max PriceUS$17.42
BuyUS$139,17026 Jul 18
Peter Cohen
EntityIndividual
Shares6,000
Max PriceUS$24.32

Ownership Breakdown


Management Team

  • Holly Kramen

    Chief Compliance Officer & Privacy Officer

    • Tenure: 1.6yrs
  • Mark Lehman

    Chief Legal Officer

  • Paul Mann

    Chief Financial Officer

    • Tenure: 0.9yrs
  • Nikolai Sopko

    Chief Scientific Officer and VP of R&D

    • Tenure: 0.9yrs
  • Rich Haerle

    Vice President of Investor Relations & Strategy

    • Tenure: 1.1yrs
  • David Seaburg (48yo)

    President of Corporate Development & Director

    • Tenure: 0.3yrs
  • David Blum

    Chief Design & Technology Officer

  • Alain Adam

    Vice President of Sales

    • Tenure: 0.9yrs
  • Richard Hague (58yo)

    Chief Operating Officer

    • Tenure: 0.2yrs
  • Denver Lough (37yo)

    Chairman

    • Tenure: 2.5yrs

Board Members

  • Jeff Dyer (59yo)

    Independent Director

    • Tenure: 2.3yrs
  • Stephen Milner (69yo)

    Chief Clinical Officer & Member of Clinical Advisory Board

    • Tenure: 2.5yrs
  • Steve Gorlin (80yo)

    Independent Director

    • Tenure: 2.3yrs
  • Jon Mogford (49yo)

    Independent Director

    • Tenure: 2.3yrs
  • Michael Grant

    Member of Clinical Advisory Board

    • Tenure: 2.5yrs
  • David Seaburg (48yo)

    President of Corporate Development & Director

    • Tenure: 0.8yrs
  • Anand Kumar

    Member of Clinical Advisory Board

    • Tenure: 2.5yrs
  • Maurice Nahabedian

    Chief Surgical Officer & Member of Clinical Advisory Board

  • Michael Neumeister (56yo)

    Chief Medical Officer & Member of Clinical Advisory Board

  • Denver Lough (37yo)

    Chairman

    • Tenure: 2.5yrs

Company Information

PolarityTE, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PolarityTE, Inc.
  • Ticker: PTE
  • Exchange: NasdaqCM
  • Founded:
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$135.829m
  • Shares outstanding: 24.65m
  • Website: Click here

Number of Employees


Location

  • PolarityTE, Inc.
  • 123 North Wright Brothers Drive
  • Salt Lake City
  • Utah
  • 84116
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTENasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2003
NJTCDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003

Biography

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicin ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/26 00:01
End of Day Share Price2019/06/25 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.